What is United Therapeutics?
United Therapeutics is a biotechnology medicines company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Biotechnology medicines
- Headquarters
- Silver Spring, MD
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: UTHR
What is United Therapeutics?
United Therapeutics is a biotechnology medicines company headquartered in Silver Spring, MD. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
United Therapeutics is a biotechnology medicines company headquartered in Silver Spring, MD. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, United Therapeutics should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does United Therapeutics offer?
United Therapeutics's profile centers on Pulmonary hypertension medicines, Organ manufacturing, Tyvaso, Remodulin.
- Pulmonary hypertension medicines· Biotechnology medicines
- Organ manufacturing· Biotechnology medicines
- Tyvaso· Biotechnology medicines
- Remodulin· Biotechnology medicines
- Clinical pipeline· Biotechnology medicines
- Transplant technology· Biotechnology medicines
How does United Therapeutics make money?
United Therapeutics makes money through commercial activity tied to biotechnology medicines.
United Therapeutics monetizes through the model common to biotechnology medicines: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads United Therapeutics?
United Therapeutics's named executives should be verified on the official leadership or investor-relations page before outreach.
- United Therapeutics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- United Therapeutics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- United Therapeutics operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact United Therapeutics's leadership?
United Therapeutics should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.unither.com- United Therapeutics investor relationsInvestor relations / corporate contactcontact via https://www.unither.com
- United Therapeutics sales or partnershipsCommercial contact routecontact via https://www.unither.com
- United Therapeutics media relationsMedia or communications contact routecontact via https://www.unither.com
How is United Therapeutics funded?
United Therapeutics's current status is Public company; Nasdaq: UTHR.
United Therapeutics's capital profile is best understood through its current public-company status: Public company; Nasdaq: UTHR. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did United Therapeutics get here?
United Therapeutics's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingUnited Therapeutics is foundedThe company begins building in biotechnology medicines.
- Scale-upCommercial footprint expandsUnited Therapeutics broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: UTHRPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are United Therapeutics's competitors?
United Therapeutics competes with larger incumbents and focused specialists in biotechnology medicines.
United Therapeutics — frequently asked questions
